Researchers discover 'chromosome scanner' that protects against cancer

Phys.org | February 26, 2019

In a new study, researchers from the University of Copenhagen have identified one of the main mechanisms behind the repair of serious damage to human DNA. A 'scanner' inside the cells decides whether or not so-called flawless DNA repair, which protects against cancer, is launched. Damage to human DNA can cause unstable genetic material and thus plays a main role in the development of cancer. Therefore, a lot of researchers are trying to learn from the cells' own protection against DNA mutations. Among other things, this is done quickly and correctly repairing DNA damage and thus avoiding tumor development. Now researchers from the University of Copenhagen have come to a step closer to understanding the cells' repair process in a new study published in the scientific journal Nature Cell Biology. For these serious damages, there are two basic repair systems, but only one of them is flawless. If this system is out of function, there is an increased risk of developing cancer following from the DNA damage to which our cells are constantly exposed. We know from mutations in so-called BRCA genes that this causes hereditary breast and ovarian cancer.

Spotlight

This infographic related to the mass spectrum in biotechnology.

Spotlight

This infographic related to the mass spectrum in biotechnology.

Related News

INDUSTRIAL IMPACT

BioAuxilium Research Expands its No-Wash THUNDER™ TR-FRET Cell Signaling Assay Portfolio

BioAuxilium Research Inc. | February 10, 2022

At the annual Society for Laboratory Automation and Screening International Conference and Exhibition in Boston, BioAuxilium Research Inc., a biotech tool company focused on facilitating access to fully validated assay kits to the biomedical research community, today announced the expansion of its no-wash THUNDER™ time-resolved Förster resonance energy transfer technology portfolio by introducing new cell signaling pathway and biomarker research assay kits, along with a panel of “mix and match” toolbox reagents. The new offerings bring the company’s portfolio to a total of 104 products. Developed and manufactured at BioAuxilium’s laboratories, the new THUNDER™ TR-FRET assay kits are ideal for studying intra- or extra-cellular signaling pathways and include key human kinases, pro-inflammatory cytokines, and a cAMP detection kit designed for the screening and characterization of G‑protein coupled receptors (GPCRs). The THUNDER™ TR-FRET toolbox reagents include europium and far-red labeled anti-species, anti-epitope, and streptavidin for enabling easy in-house assay development. “The addition of the new THUNDER™ TR-FRET assays and reagents demonstrate our capacity to continue to grow a focused portfolio of high quality yet affordable assays for both basic research and drug discovery. In addition, we are committed to addressing the reproducibility crisis in biomedical research by continuing to provide reliable research tools that enable the generation of highly reproducible results, much faster.” Jaime Padros, PhD, President, BioAuxilium Research BioAuxilium’s THUNDER™ TR-FRET technology is a robust, proprietary platform based on a FRET pair showing an enhanced spectral compatibility and TR-FRET signal, optimal antibody pairs selected specifically for TR-FRET, and a panel of optimized lysis and assay buffers. In addition, all assays use a simplified protocol that dramatically decreases hands-on time and assay variability and is easily amenable to automation for high-throughput screening. All THUNDER™ TR-FRET products are extensively validated to ensure specificity, sensitivity, and reproducibility using real-life biological samples. About BioAuxilium Research Inc. BioAuxilium is a private Canadian biotechnology tool company founded by expert assay scientists. It focuses on developing and manufacturing top-quality, highly validated assay kits that accelerate biomedical research. BioAuxilium’s kits are based on its enhanced proprietary THUNDER™ TR-FRET technology. They are offered at an outstanding value and are accompanied by information-rich datasheets and expert technical support. Bioauxilium also provides customized services in assay development using diverse technologies on a contract basis.

Read More

RESEARCH

Synthace Unveils First Life Sciences R&D Cloud Addressing Complexity, Speed & Reproducibility for Scientists

Synthace | August 03, 2021

Synthace, a leading life sciences software company, today announced the first life sciences R&D cloud that includes a no-code software platform addressing the largest barriers to innovation that R&D life scientists currently face. With the release of this new platform, Synthace is also the first vendor to enable scientists to automate experimentation and insight sharing in a unified, global R&D environment. Scientists can now focus on asking the most impactful questions and unlock the true potential of biology. To solve humanity’s hardest problems, such as delivering breakthrough therapies or alternative food sources, the life sciences industry is under tremendous pressure to simultaneously overcome biology’s complexity, accelerate speed to scientific insight, and ensure the reproducibility of experiments. Synthace alleviates these challenges by empowering scientists to improve and accelerate decision-making with more statistically powerful, automated experiments that can minimize human error. Furthermore, Synthace’s cloud platform leverages intelligent, dynamic automation to produce the highest quality data sets that are primed for machine learning (ML) and other advanced analyses to lead to better insights. With Synthace, the life sciences can now benefit from a quantum leap in experimentation capabilities, accelerating development timelines that would have previously been impossible. Customers Accelerate R&D with Synthace Ipsen has been using Synthace to automate the design and construction of therapeutic candidates. With Synthace, Ipsen produced approximately 90 constructs five times faster than previous methods, substantially increasing the number of molecules entering the screening cascade. The platform also achieved a 10-fold reduction in costs associated with DNA synthesis. Karen Bunting, Director of Protein Sciences at Ipsen commented, “Synthace sits very well at the beginning of our drug discovery process. It allows us to explore larger drug design space by simplifying planning and production of multiple molecule variants with combinatorial construct assembly. These throughput improvements help us deliver well-tolerated and effective therapeutic solutions more rapidly to our patients.” Microsoft Research also uses Synthace to automatically generate biological data at a volume that allows its ML algorithms to rapidly improve. As part of reporting on advancements in programming biological systems, a member of its Biocomputation Group noted: “Synthace really comes into its own when we’re performing experiments with complex layouts like combinatorial construct assembly and design of experiments. When we’re building 12 constructs at a time, Synthace automates all the planning that would go into setting up such an experiment and allows it to become routine.” Synthace Life Sciences R&D Cloud The platform provides end-to-end management of the experimental lifecycle, from design through execution to data visualization and knowledge transfer. Synthace adheres to FAIR principles to support interoperability with other major lab informatics platforms to ensure streamlined data management for all of its customers. Only the Synthace Life Sciences R&D Cloud delivers: Complete experimental design, planning and automation, requiring no coding expertise. Scientists can define more informative and impactful experiments that would otherwise be impossible to run and easily implement Quality by Design (QbD) and Design of Experiments (DOE). Seamless, cloud-based data capture, processing, and visualization. R&D teams can deliver deeper and faster insights from fully contextualized, machine learning-ready data sets that are automatically generated from the laboratory. Minimal deployment and onboarding. Customers experience rapid time-to-insight through Synthace’s out-of-the-box platform features and pre-validated protocols for common applications such as ELISA and high-throughput purification, helping them shorten R&D cycles and study more candidates per program. About Synthace Synthace is a life sciences software company enabling life science the way it should be done. Delivering a life sciences R&D cloud to scientists who want to innovate faster, the Synthace platform seamlessly automates experimentation and insight sharing so that scientists can focus on asking the most impactful questions to unlock the true potential of biology. Top global pharmaceuticals, high-growth biotech companies, leading CDMOs, and innovators in artificial intelligence all turn to Synthace to discover solutions to humanity’s hardest problems.

Read More

Sartorius Stedim Biotech Closes Acquisition of Slovenian Purification Specialist BIA Separations

Sartorius | November 03, 2020

Sartorius Stedim Biotech (SSB), a leading partner of the biopharma industry, successfully closed the acquisition of the Slovenian purification specialist BIA Separations. The transaction was completed on November 2, 2020, after receiving the required approvals. "BIA's portfolio is highly complementary to Sartorius Stedim Biotech. We are thus creating an excellent offering for the manufacturing of gene therapies and other advanced therapies, and are pleased to welcome 120 new employees," said Dr. Joachim Kreuzburg, Chairman of the Board and CEO of Sartorius Stedim Biotech. The total purchase price of the transaction is 360 million euros of which 240 million euros were paid in cash and 120 million euros in SSB shares. Both parties have further agreed on three tranches of earn-out payments based on performance over the next five financial years. SSB has been preparing to integrate BIA Separations so this can now be initiated despite the special conditions prevailing during the pandemic. BIA Separations develops and manufactures market-leading products for purification and analysis of large biomolecules, such as viruses, plasmids and mRNA, which are used in cell and gene therapies and other advanced therapies. BIA's technology for manufacturing-scale purification is already used in production of the first commercialized advanced therapeutics, and the company also has a strong presence with such novel drug candidates in the clinical pipeline. Expecting continued very strong double-digit sales growth over the next few years, BIA is forecasted to earn sales revenue of approx. 25 million euros in 2020 at profit margins that will be accretive to the underlying EBITDA margin of the Sartorius Stedim Biotech Group. The transaction is not expected to have any material impact on Sartorius Stedim Biotech's 2020 results.

Read More